Form 4: Recursion Pharma Officer Sells $548K in Stock

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, sold 124,403 shares of Class A Common Stock for approximately $548,600 under a pre-arranged trading plan.

Summary

• Najat Khan, a Director and the Chief R&D Commercial Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported a sale of company stock.
• On December 22, 2025, Khan disposed of 124,403 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $4.4098 per share, with individual trades ranging from $4.30 to $4.48.
• The total value of the shares sold is approximately $548,600.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Khan on September 22, 2025.
• Following this transaction, Khan directly beneficially owns 611,135 shares of Class A Common Stock.
• Khan also holds several stock options: 169,851 options with an exercise price of $4.96, 420,226 options with an exercise price of $7.25, and 993,944 options with an exercise price of $7.34, all for Class A Common Stock.

Sentiment

Score: 4

Explanation: While the sale was pre-planned under a 10b5-1 plan, insider selling, especially by a key officer, can still be viewed with caution by the market. The sale price being below some option exercise prices adds a slight negative nuance, though it doesn't necessarily reflect a lack of confidence in the long term.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, which indicates the sale was pre-scheduled and not based on immediate, non-public information, potentially mitigating concerns about insider sentiment.

Negatives

• An insider sale of 124,403 shares, valued at over half a million dollars, could be perceived by the market as a lack of confidence in the company's near-term prospects, despite being pre-planned.
• The sale price of $4.4098 is below the exercise prices of some of the outstanding stock options held by the reporting person ($4.96, $7.25, $7.34), which might raise questions about the perceived value of the stock.

Risks

• Market perception of insider selling, even when pre-planned, can sometimes lead to negative sentiment or downward pressure on the stock price.
• The sale of a significant number of shares by a key executive could be interpreted as a signal regarding future company performance or valuation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. However, insider trading activity is often monitored by investors in the biotechnology and pharmaceutical sectors as a potential indicator of management's confidence.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal regarding the company's valuation or future prospects, potentially influencing their investment decisions.
• Employees might observe the trading activity of senior management, which could subtly affect morale or perception of company stability.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Sale, Najat Khan, 10b5-1 Plan, Biotechnology, Pharmaceuticals